
APPENDIX IV

STATUTORY AND GENERAL INFORMATION

A. FURTHER INFORMATION ABOUT OUR GROUP

1. Incorporation

Our Company was established as a limited liability company under the laws of the PRC on July 11, 2018 (under the former name Harbin Gaozhentang TCM Clinic Co., Ltd.* (哈爾濱膏珍堂中醫診所有限公司)) and was converted into a joint stock limited company on August 8, 2025 under the laws of the PRC. As of the Latest Practicable Date, the registered capital of the Company was RMB15,845,352.

Our registered address is 1-2/F., No. 145, Xiangfang Dajie, Xiangfang District, Harbin, Heilongjiang Province, PRC.

As the Company was incorporated in the PRC, its operations are subject to the relevant laws and regulations of the PRC. A summary of the relevant aspects of laws and regulations of the PRC and the Articles of Association is set out in Regulatory Overview and Appendix III, respectively.

2. Changes in Share Capital

The following sets out the changes in the share capital of our Company within two years immediately preceding the date of this document:

Prior to its conversion into a joint stock limited company, our Company, in its form as a limited liability company, increased its registered capital through several rounds of capital injection completed in 2024 and 2025.

On August 8, 2025, our Company was converted into a joint stock limited company with a registered capital of RMB15,845,352, divided into 15,845,352 shares with a nominal value of RMB1.00 each, which were issued to the promoters based on the audited net assets as of April 30, 2025.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

3. Further Information about Our Principal Subsidiaries

A summary of the corporate information and the particulars of our major subsidiaries are set out in the Accountants’ Report, the text of which is set out in Appendix I. The following subsidiaries were incorporated within the two years immediately preceding the date of this document:

<u>Name</u>	<u>Dates of incorporation</u>	<u>Place of incorporation</u>	<u>Registered capital/share capital</u> (RMB)
Shenyang Yuhong Gaozhentang Lvshan Traditional Chinese Medicine Outpatient Department Co., Ltd. (瀋陽於洪膏珍堂閭山 中醫門診部有限公司)	September 23, 2025	Chinese Mainland	500,000
Shenyang Gaozhentang Changqing Medical Service Co., Ltd. (瀋陽膏珍堂常青醫療服務 有限公司)	September 25, 2025	Chinese Mainland	500,000
Tangshan Gaozhentang Traditional Chinese Medicine Clinic Co., Ltd. (唐山膏珍堂中醫門 診有限公司)	April 16, 2024	Chinese Mainland	1,000,000
Tangshan Gaozhentang Lu Bei Comprehensive Outpatient Department Co., Ltd. (唐山膏珍堂 錄北綜合門診部有限公司)	June 16, 2025	Chinese Mainland	500,000
Anshan Gaozhentang Medical Service Co., Ltd. (鞍山膏珍堂醫療服務有限公司)	August 20, 2024	Chinese Mainland	500,000
Zhaodong Gaozhentang Traditional Chinese Medicine Clinic Service Co., Ltd. (肇東膏珍 堂中醫診所服務有限公司)	August 8, 2024	Chinese Mainland	500,000
Dandong Gaozhentang Yuan Bao Medical Service Co., Ltd. (丹東膏珍堂源寶醫療服務 有限公司)	April 3, 2025	Chinese Mainland	500,000
Changchun Gaozhentang Shankang Medical Service Co., Ltd. (長春膏珍堂善康醫療服務 有限公司)	April 17, 2025	Chinese Mainland	100,000
Changchun Gaozhentang De Kang Medical Service Co., Ltd. (長春膏珍堂德康醫療服務 有限公司)	April 17, 2025	Chinese Mainland	100,000
Changchun Gaozhentang Deyu Medical Service Co., Ltd. (長春膏珍堂德譽醫療服務有限公 司)	September 15, 2025	Chinese Mainland	100,000
Changchun High-Tech Industrial Development Zone Gaozhentang Shanyu Traditional Chinese Medicine Clinic Co., Ltd. (長春高新 技術產業開發區膏珍堂善譽中醫門診部有限 公司)	September 23, 2025	Chinese Mainland	1,000,000
Yuyantang (Beijing) Hospital Management Co., Ltd. (譽研堂(北京)醫院管理有限公司)	June 3, 2024	Chinese Mainland	2,000,000

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

<u>Name</u>	<u>Dates of incorporation</u>	<u>Place of incorporation</u>	<u>Registered capital/share capital</u> (RMB)
Harbin Gaozhentang Xinyuan Traditional Chinese Medicine Clinic Co., Ltd. (哈爾濱膏珍堂鑫源中醫診所有限公司)	August 12, 2024	Chinese Mainland	500,000
Harbin Gaozhentang Pingfang Traditional Chinese Medicine Clinic Co., Ltd. (哈爾濱膏珍堂平坊中醫診所有限公司)	November 14, 2024	Chinese Mainland	500,000
Harbin Gaozhentang Development Traditional Chinese Medicine Clinic Co., Ltd. (哈爾濱膏珍堂開發中醫門診有限公司)	November 19, 2024	Chinese Mainland	500,000
Tianjin Gaozhentang Traditional Chinese Medicine Clinic Co., Ltd. (天津膏珍堂中醫門診有限公司)	November 27, 2024	Chinese Mainland	500,000
Tianjin Binhai Gaozhentang Comprehensive Outpatient Department Co., Ltd. (天津濱海膏珍堂綜合門診部有限公司)	June 11, 2025	Chinese Mainland	500,000
Tianjin Hexi Gaozhentang Traditional Chinese Medicine Clinic Co., Ltd. (天津河西膏珍堂中醫門診部有限公司)	October 15, 2025	Chinese Mainland	500,000
Gaozhentang (Heilongjiang) Health Technology Co., Ltd. (膏珍堂(黑龍江)健康科技有限公司)	January 13, 2025	Chinese Mainland	200,000
Harbin Gaozhentang Limin Integrated Traditional Chinese and Western Medicine Clinic Co., Ltd. (哈爾濱膏珍堂利珞中西醫結合門診有限公司)	February 26, 2025	Chinese Mainland	500,000
Jinan Gaozhentang Medical Service Co., Ltd. (濟南膏珍堂醫療服務有限公司)	April 23, 2025	Chinese Mainland	500,000
Qingdao Gaozhentang Medical Service Co., Ltd. (青島膏珍堂醫療服務有限公司)	April 10, 2024	Chinese Mainland	1,000,000
Qingdao Gaozhentang Hongshan Traditional Chinese Medicine Clinic Co., Ltd. (青島膏珍堂弘山中醫診所有限公司)	August 13, 2025	Chinese Mainland	500,000
Weihai Gaozhentang Traditional Chinese Medicine Clinic Co., Ltd. (威海膏珍堂中醫門診有限公司)	May 13, 2024	Chinese Mainland	1,000,000
Yantai Gaozhentang Clinic Co., Ltd. (煙台膏珍堂診所有限公司)	July 9, 2024	Chinese Mainland	1,000,000
Yantai Gaozhentang Limin Clinic Co., Ltd. (煙台膏珍堂利民診所有限公司)	May 30, 2025	Chinese Mainland	500,000
Yantai Gaozhentang Nanda Traditional Chinese Medicine Clinic Co., Ltd. (煙台膏珍堂楠大中醫診所有限公司)	August 20, 2025	Chinese Mainland	500,000
Zibo Gaozhentang Medical Service Co., Ltd. (淄博膏珍堂醫療服務有限公司)	May 22, 2025	Chinese Mainland	500,000

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Name	Dates of incorporation	Place of incorporation	Registered capital/share capital (RMB)
Harbin Gaozhentang Shangzhi Specialized Outpatient Clinic Co., Ltd. (哈爾濱膏珍堂尚 質專科門診有限公司)	July 30, 2025	Chinese Mainland	500,000
Harbin Gaozhentang Pujiang Specialized Outpatient Clinic Co., Ltd. (哈爾濱膏珍堂普 江專科門診有限公司)	August 19, 2025	Chinese Mainland	500,000
Harbin Gaozhentang Sanhe Traditional Chinese Medicine Clinic Co., Ltd. (哈爾濱膏珍堂仁禾 中醫診所有限公司)	August 19, 2025	Chinese Mainland	500,000
Harbin Gaozhentang Qingming Specialized Outpatient Clinic Co., Ltd. (哈爾濱膏珍堂青 茗專科門診有限公司)	September 10, 2025	Chinese Mainland	500,000
Zibo Gaozhentang Huaguang Medical Service Co., Ltd. (淄博膏珍堂樺光醫療服務有限公 司)	December 4, 2025	Chinese Mainland	500,000
Weihai Gaozhentang Kai Fa Traditional Chinese Medicine Clinic Co., Ltd. (威海膏珍堂楷發中 醫診所有限公司)	December 4, 2025	Chinese Mainland	500,000
Shijiazhuang Gaozhentang Huaizhong Medical Service Co., Ltd. (石家莊膏珍堂淮中醫療服 務有限公司)	December 11, 2025	Chinese Mainland	500,000
Yuyantang (Harbin) Health Technology Co., Ltd. (譽研堂(哈爾濱)健康科技有限公司) . .	December 29, 2025	Chinese Mainland	500,000
Shijiazhuang Gaozhentang Medical Service Co., Ltd. (石家莊膏珍堂醫療服務有限公司)	November 25, 2025	Chinese Mainland	1,000,000
Tangshan Gaozhentang Dali Medical Service Co., Ltd. (唐山膏珍堂大禮醫療服務有限公 司)	January 12, 2026	Chinese Mainland	500,000
Jining Gaozhentang Medical Service Co., Ltd. (濟寧膏珍堂醫療服務有限公司)	January 14, 2026	Chinese Mainland	500,000
Anshan Gaozhentang Minsheng Medical Service Co., Ltd. (鞍山膏珍堂珉生醫療服務有限公 司)	January 22, 2026	Chinese Mainland	500,000
Tianjin Gaozhentang Nankai Traditional Chinese Medicine Clinic Co., Ltd. (天津膏珍堂楠楷中 醫門診有限公司)	February 6, 2026	Chinese Mainland	500,000
Zhengzhou Gaozhentang Traditional Chinese Medicine Clinic Co., Ltd. (鄭州膏珍堂中醫門 診有限公司)	February 26, 2026	Chinese Mainland	1,000,000
Weifang Kuiwen Gaozhentang Clinic Co., Ltd. (濰坊奎文膏珍堂診所有限公司)	April 10, 2026	Chinese Mainland	500,000
Nanjing Xuanwu Gaozhentang Clinic Co., Ltd. (南京玄武膏珍堂診所有限公司)	April 16, 2026	Chinese Mainland	500,000

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

<u>Name</u>	<u>Dates of incorporation</u>	<u>Place of incorporation</u>	<u>Registered capital/share capital</u> (RMB)
Shenyang Gaozhentang Hunnan Medical Service Co., Ltd. (瀋陽膏珍堂渾楠醫療服務有限公司)	April 30, 2026	Chinese Mainland	500,000
Weifang Kuiwen Gaozhentang Medical Service Co., Ltd. (濰坊奎文膏珍堂醫療服務有限公司)	May 14, 2026	Chinese Mainland	500,000
Yantai Gaozhentang Fushan Traditional Chinese Medicine Clinic Co., Ltd. (煙台膏珍堂伏山中醫診所有限公司)	May 19, 2026	Chinese Mainland	500,000
Yantai Gaozhentang Fuhai Medical Service Co., Ltd. (煙台膏珍堂傅海醫療服務有限公司) . .	May 21, 2026	Chinese Mainland	500,000
Jining Gaozhentang Rencheng Clinic Co., Ltd. (濟寧膏珍堂仁成診所有限公司)	June 3, 2026	Chinese Mainland	500,000
Jinan Gaozhentang Tianqiao Clinic Co., Ltd. (濟南膏珍堂天橋診所有限公司)	June 8, 2026	Chinese Mainland	500,000
Tangshan Gaozhentang Longze Medical Service Co., Ltd. (唐山膏珍堂龍澤醫療服務有限公司)	June 15, 2026	Chinese Mainland	500,000
Nanjing Xuanwu Gaozhentang Siping Traditional Chinese Medicine Clinic Co., Ltd. (南京玄武膏珍堂泗坪中醫診所有限公司)	June 29, 2026	Chinese Mainland	500,000
Baoding Gaozhentang Medical Service Co., Ltd. (保定膏珍堂醫療服務有限公司)	July 7, 2026	Chinese Mainland	500,000
Donggang Gaozhentang Dadong Medical Service Co., Ltd. (東港膏珍堂大棟醫療服務有限公司)	July 16, 2026	Chinese Mainland	500,000

Save as disclosed above, there has been no alteration in the share capital of our subsidiaries within two years immediately preceding the date of this document.

4. Resolutions of our Shareholders

At the general meeting of the Shareholders held on January 8, 2026, the following resolutions, among other things, were duly passed:

- (a) the issue by the Company of H Shares with a nominal value of RMB0.125 each and such H Shares be [REDACTED] on the Main Board of the Hong Kong Stock Exchange;
- (b) the number of H Shares to be issued shall be no [REDACTED] of the total issued share capital of our Company as enlarged by the issuance (or up to approximately [REDACTED] if the [REDACTED] is fully exercised);

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (c) authorization of the Board or its authorized individual to handle all matters relating to, among other things, the [REDACTED], the issue and the [REDACTED] of H Shares on the Hong Kong Stock Exchange; and
- (d) subject to the completion of the [REDACTED], the conditional adoption of the revised Articles of Association, which shall become effective on the [REDACTED].

B. FURTHER INFORMATION ABOUT OUR BUSINESS

1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) have been entered into by members of our Group within the two years preceding the date of this document and are or may be material:

- (a) an equity increase agreement (增資協議) dated June 25, 2024 entered into among the Company and Hainan Youzhuo, pursuant to which Hainan Youzhuo agreed to subscribe for an increased registered capital of RMB154,600 for a consideration of RMB1,391,400;
- (b) an equity increase agreement (增資協議) dated March 31, 2025 entered into among the Yuyantang Investment, Zhitongdaohe Investment, Hainan Youzhuo and Zhitongdaohe Yidai, our employee incentive platform, pursuant to which, Zhitongdaohe Yidai agreed to subscribe for an increased registered capital of RMB845,352 for the consideration of RMB3,592,746; and

2. Intellectual Property Rights

(a) Trademarks

As of May 31, 2026, we had registered the following trademarks which we consider to be or may be material to our business:

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
1		PRC	The Company	44	87783604	April 27, 2036
2		PRC	The Company	5	87789995	April 20, 2036
3		PRC	The Company	35	87781452	April 27, 2036
4		PRC	The Company	44	87743849	March 13, 2036
5		PRC	The Company	35	87743833	March 27, 2036
6	譽研堂	PRC	The Company	17	87175355	February 20, 2036
7	譽研堂	PRC	The Company	1	87165321	May 6, 2036
8	譽研堂	PRC	The Company	34	87181427	February 20, 2036

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
9	誉研堂	PRC	The Company	26	87175384	February 20, 2036
10	誉研堂	PRC	The Company	29	87178712	March 27, 2036
11	誉研堂	PRC	The Company	31	87184959	February 20, 2036
12	誉研堂	PRC	The Company	15	87175340	February 20, 2036
13	誉研堂	PRC	The Company	23	87167788	February 20, 2036
14	誉研堂	PRC	The Company	10	87169404	February 20, 2036
15	誉研堂	PRC	The Company	2	87171870	May 20, 2036
16	誉研堂	PRC	The Company	39	87170188	February 20, 2036
17	誉研堂	PRC	The Company	9	87178684	April 6, 2036
18	誉研堂	PRC	The Company	14	87169840	February 20, 2036
19	誉研堂	PRC	The Company	18	87172009	February 20, 2036
20	誉研堂	PRC	The Company	20	87169910	February 20, 2036
21	誉研堂	PRC	The Company	28	87182681	February 20, 2036
22	誉研堂	PRC	The Company	36	87175883	February 20, 2036
23	誉研堂	PRC	The Company	37	87176455	February 20, 2036
24	誉研堂	PRC	The Company	40	87178558	February 20, 2036
25	誉研堂	PRC	The Company	4	87169721	February 20, 2036
26	誉研堂	PRC	The Company	38	87179024	February 20, 2036
27	誉研堂	PRC	The Company	3	87178784	May 6, 2036
28	誉研堂	PRC	The Company	13	87165445	February 20, 2036
29	誉研堂	PRC	The Company	32	87177699	March 27, 2036
30	誉研堂	PRC	The Company	41	87165227	February 20, 2036
31	誉研堂	PRC	The Company	21	87184059	February 20, 2036
32	誉研堂	PRC	The Company	45	87165896	February 20, 2036
33	誉研堂	PRC	The Company	4	87175128	February 20, 2036
34	誉研堂	PRC	The Company	22	87180087	February 20, 2036
35	誉研堂	PRC	The Company	19	87172024	February 20, 2036
36	誉研堂	PRC	The Company	27	87167817	February 20, 2037
37	誉研堂	PRC	The Company	8	87175300	April 6, 2037
38	膏珍堂	PRC	The Company	30	75129681	June 6, 2034
39	膏珍堂	PRC	The Company	5	75118865	June 6, 2034
40	膏珍堂	PRC	The Company	30	67848197A	October 6, 2033
41	誉研堂	PRC	The Company	44	66101223	January 20, 2033
42	膏珍堂	PRC	The Company	3	65141176	January 20, 2033
43	膏珍堂	PRC	The Company	34	65148412	December 6, 2032
44	膏珍堂	PRC	The Company	30	65168211	February 13, 2033
45		PRC	The Company	5	65161098	April 6, 2033
46	膏珍堂	PRC	The Company	19	65147630	December 6, 2032
47	膏珍堂	PRC	The Company	34	62132125	July 13, 2032

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
48	膏珍堂	PRC	The Company	37	62140783	October 6, 2032
49	膏珍堂	PRC	The Company	12	62130024	July 13, 2032
50	膏珍堂	PRC	The Company	13	62120210	July 6, 2032
51	膏珍堂	PRC	The Company	15	62133385	July 13, 2032
52	膏珍堂	PRC	The Company	8	62141280	August 20, 2032
53	膏珍堂	PRC	The Company	22	62117771	July 13, 2032
54	膏珍堂	PRC	The Company	20	62127145	November 6, 2032
55	膏珍堂	PRC	The Company	26	62140706	July 13, 2032
56	膏珍堂	PRC	The Company	28	62144970	July 20, 2032
57	膏珍堂	PRC	The Company	14	62137298	July 6, 2032
58	膏珍堂	PRC	The Company	17	62123513	July 13, 2032
59	膏珍堂	PRC	The Company	19	62133015	July 20, 2032
60	膏珍堂	PRC	The Company	23	62117693	July 13, 2032
61	膏珍堂	PRC	The Company	31	62134767	July 13, 2032
62	膏珍堂	PRC	The Company	24	62096120	July 13, 2032
63	膏珍堂	PRC	The Company	11	62117068	November 20, 2033
64	膏珍堂	PRC	The Company	6	62105401A	December 27, 2033
65	膏珍堂	PRC	The Company	35	62090508	July 13, 2032
66	膏珍堂	PRC	The Company	42	62092998	July 13, 2032
67	膏珍堂	PRC	The Company	7	62089493	July 27, 2032
68	膏珍堂	PRC	The Company	43	62116146	July 20, 2032
69	膏珍堂	PRC	The Company	2	62094982	July 13, 2032
70	膏珍堂	PRC	The Company	1	62112334	February 27, 2033
71	膏珍堂	PRC	The Company	44	62112227	September 20, 2032
72	膏珍堂	PRC	The Company	5	62109466A	October 13, 2032
73	膏珍堂	PRC	The Company	39	62093055	July 13, 2032
74	膏珍堂	PRC	The Company	9	62066777	July 6, 2032
75	膏珍堂	PRC	The Company	41	62065635	July 6, 2032
76	膏珍堂	PRC	The Company	45	62068859	July 6, 2032
77	膏珍堂	PRC	The Company	27	62066928	July 6, 2032
78	膏珍堂	PRC	The Company	29	62070113	July 6, 2032
79	膏珍堂	PRC	The Company	10	62084077	July 6, 2032
80	膏珍堂	PRC	The Company	21	62077179	July 6, 2032
81	膏珍堂	PRC	The Company	16	62063643	July 6, 2032
82	膏珍堂	PRC	The Company	40	62084958	July 13, 2032
83	膏珍堂	PRC	The Company	4	62057272	June 27, 2032
84	膏珍堂	PRC	The Company	18	62043368	July 13, 2032
85	膏珍堂	PRC	The Company	38	57747337	January 13, 2032
86	膏珍堂	PRC	The Company	39	57773871	January 20, 2032

APPENDIX IV STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
87		PRC	The Company	5	57776974A	March 13, 2032
88		PRC	The Company	43	57766664	March 27, 2032
89	膏珍堂	PRC	The Company	42	57777419	January 13, 2032
90		PRC	The Company	42	57751967	January 20, 2032
91	膏珍云医	PRC	The Company	5	57766868	January 20, 2032
92	膏珍堂	PRC	The Company	36	57768429	January 20, 2032
93		PRC	The Company	36	57747602	January 13, 2032
94	膏珍堂	PRC	The Company	16	57769803	January 13, 2032
95		PRC	The Company	40	57759793	January 13, 2032
96		PRC	The Company	9	57747205	January 20, 2032
97	膏珍堂	PRC	The Company	40	57759784	January 13, 2032
98		PRC	The Company	38	57747319	January 13, 2032
99		PRC	The Company	39	57768452	January 20, 2032
100	膏珍堂	PRC	The Company	5	57742684	February 13, 2032
101	膏珍堂	PRC	The Company	5	57650373A	March 20, 2032
102	膏珍云医	PRC	The Company	5	57477225	January 20, 2032
103	膏珍云医	PRC	The Company	45	51834909	August 27, 2031
104	膏珍云医	PRC	The Company	33	50651426	August 13, 2031
105	膏珍云医	PRC	The Company	10	50643842	July 20, 2031
106	膏珍云医	PRC	The Company	40	50638791	August 20, 2031
107	膏珍云医	PRC	The Company	29	50646588	July 20, 2031
108	膏珍云医	PRC	The Company	43	50648195	September 13, 2031
109	膏珍云医	PRC	The Company	21	50645430	August 20, 2031
110	膏珍云医	PRC	The Company	41	50630824	August 6, 2031
111	膏珍云医	PRC	The Company	3	50626978	August 13, 2031
112	膏珍云医	PRC	The Company	30	50651161	August 13, 2031
113	膏珍云医	PRC	The Company	11	50631143	August 6, 2031
114	膏珍云医	PRC	The Company	36	50620870	July 6, 2031
115	膏珍云医	PRC	The Company	24	50637489	August 6, 2031
116	膏珍云医	PRC	The Company	25	50629846	August 6, 2031
117	膏珍云医	PRC	The Company	38	50620920	August 20, 2031

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
118	膏珍云医	PRC	The Company	39	50648593	August 13, 2031
119	膏珍云医	PRC	The Company	32	50620823	August 20, 2031
120	誉研云医	PRC	The Company	44	47698126	April 13, 2031
121	皇家益寿	PRC	The Company	44	46183638	March 27, 2031
122	皇家益寿	PRC	The Company	25	46202282	February 13, 2032
123	皇家益寿	PRC	The Company	29	46201891	March 27, 2031
124	皇家益寿	PRC	The Company	41	46187085	March 27, 2031
125	皇家益寿	PRC	The Company	42	46200017	March 27, 2031
126	皇家益寿	PRC	The Company	40	46179526	March 27, 2031
127	皇家益寿	PRC	The Company	24	46201312	March 27, 2031
128	皇家益寿	PRC	The Company	30	46211064	March 27, 2031
129	皇家益寿	PRC	The Company	21	46184101	March 27, 2031
130	皇家益寿	PRC	The Company	11	46205496	March 27, 2031
131	皇家益寿	PRC	The Company	43	46142926	January 27, 2031
132	皇家益寿	PRC	The Company	10	46160738	January 27, 2031
133	皇家益寿	PRC	The Company	32	46141068	January 27, 2031
134	皇家益寿	PRC	The Company	3	46147322	January 27, 2031
135	皇家益寿	PRC	The Company	38	46137457	January 27, 2031
136		PRC	The Company	44	44871580	December 6, 2030
137	膏珍云医	PRC	The Company	44	44878135	December 6, 2030
138	膏珍云医	PRC	The Company	35	44879372	December 20, 2030
139		PRC	The Company	35	44898129	December 27, 2030
140	膏珍云医	PRC	The Company	9	44817582	December 27, 2030
141	膏珍云医	PRC	The Company	5	44817574	December 27, 2030
142	膏珍云医	PRC	The Company	42	44824426	December 6, 2030
143		PRC	The Company	32	43850909	December 6, 2030
144		PRC	The Company	16	43867120	November 6, 2030
145		PRC	The Company	30	43861790	January 27, 2031
146		PRC	The Company	25	43846855	November 20, 2030
147		PRC	The Company	21	43850396	January 27, 2031
148		PRC	The Company	10	43864898	November 6, 2030

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
149		PRC	The Company	11	43857988	November 6, 2030
150		PRC	The Company	3	43855270	February 6, 2031
151		PRC	The Company	33	43847441	November 20, 2030
152		PRC	The Company	29	43846872	November 20, 2030
153		PRC	The Company	41	43856796	November 6, 2030
154		PRC	The Company	24	43858102	November 6, 2030
155	沈城仁心堂	PRC	The Company	35	41898138	August 6, 2030
156		PRC	The Company	35	41903784	September 13, 2030
157	誉研堂	PRC	The Company	25	41229105	June 6, 2030
158	誉研堂	PRC	The Company	31	41217218	May 20, 2030
159	誉研堂	PRC	The Company	40	41205134	May 20, 2030
160	誉研堂	PRC	The Company	29	41217200	June 13, 2030
161	誉研堂	PRC	The Company	9	41208710	June 13, 2030
162	誉研堂	PRC	The Company	16	41228410	June 13, 2030
163	誉研堂	PRC	The Company	24	41235573	May 20, 2030
164	誉研堂	PRC	The Company	36	41209186	June 6, 2030
165	誉研堂	PRC	The Company	33	41199920	June 6, 2030
166	誉研堂	PRC	The Company	3	41209955	September 6, 2030
167	誉研堂	PRC	The Company	41	41228572	May 20, 2030
168	誉研堂	PRC	The Company	10	41229560	May 20, 2030
169	皇家益寿	PRC	The Company	35	39758289	April 13, 2030
170	誉研堂	PRC	The Company	44	39743823	June 6, 2030
171	誉研堂	PRC	The Company	30	39746507	July 13, 2030
172	誉研堂	PRC	The Company	35	39750002	June 27, 2030
173	皇家益寿	PRC	The Company	5	38477632	February 27, 2030
174		PRC	The Company	44	35706108A	December 27, 2029
175		PRC	The Company	35	35706109A	December 27, 2029
176	膏珍堂	PRC	The Company	32	35345173	August 6, 2029
177	膏珍堂	PRC	The Company	29	35345175	August 6, 2029
178	膏珍堂	PRC	The Company	11	35345179	August 6, 2029

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

No.	Trademark	Place of registration	Rights holder	Category	Registration number	Expiration date
179	膏珍堂	PRC	The Company	30	35345174A	September 20, 2029
180	膏珍堂	PRC	The Company	24	35345177	September 6, 2029
181	膏珍堂	PRC	The Company	10	35345180	August 6, 2029
182	膏珍堂	PRC	The Company	25	35345176	August 6, 2029
183	膏珍堂	PRC	The Company	3	35345182A	September 20, 2029
184	膏珍堂	PRC	The Company	41	35345172	August 6, 2029
185	膏珍堂	PRC	The Company	43	35345171A	September 20, 2029
186	膏珍堂	PRC	The Company	21	35345178	August 6, 2029
187	膏珍堂	PRC	The Company	9	35345181	August 6, 2029
188	皇家益寿	PRC	The Company	5	33119980	September 6, 2029
189	誉研堂	PRC	The Company	5	32913577	June 20, 2029
190	皇家益寿	PRC	The Company	30	30688208	February 13, 2029
191	膏珍堂	PRC	The Company	35	24039231	May 6, 2028
192	膏珍堂	PRC	The Company	44	24038948	May 6, 2028
193	泽宝堂	PRC	The Company	35	23732933	July 27, 2028
194	清雪通健	PRC	The Company	5	18322635	December 20, 2026

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

As of the Latest Practicable Date, we had registered for the registration of the following trademark which we consider to be material in relation to our business:



Hong Kong	The Company	5, 30, 35, 44	307117920	Expiry date: December 4, 2035
Hong Kong	The Company	5, 30, 35, 44	307117920	Expiry date: December 4, 2035
Hong Kong	The Company	5, 30, 35, 44	307156684	Expiry Date: January 11, 2036
Hong Kong	The Company	5, 30, 35, 44	307156684	Expiry Date: January 11, 2036

(b) Copyright

As of May 31, 2026, we had registered the following copyrights which we consider to be or may be material to our business:

(i) Software Copyright

No.	Copyright	Place of Registration	Copyright owner	Registration No.	Date of Registration	Date of Publication	Expiration date
1	BI Intelligent Data Analysis System	PRC	The Company	2025SR2221769	November 18, 2025	Not published	–
2	Digitalized Membership Operation Management Platform	PRC	The Company	2025SR2220310	November 18, 2025	Not published	–
3	Digitalized Store Data Analysis System	PRC	The Company	2025SR2221756	November 18, 2025	Not published	–
4	TCM Pulse Diagnosis AI Intelligent Diagnosis System.	PRC	The Company	2025SR2186323	November 12, 2025	Not published	–
5	TCM Decoction Process Optimization System	PRC	The Company	2025SR2186405	November 12, 2025	Not published	–
6	Intelligent Electronic Medical Record Management System	PRC	The Company	2025SR2186324	November 12, 2025	Not published	–
7	TCM Intelligent Formula Recommendation System	PRC	The Company	2025SR2186409	November 12, 2025	Not published	–
8	TCM Intelligent Syndrome Differentiation Assistance System.	PRC	The Company	2025SR2070218	October 24, 2025	Not published	–
9	TCM Decoction Intelligent Tracking Management System.	PRC	The Company	2025SR2069671	October 24, 2025	Not published	–
10	TCM Processing AI Quality Identification System.	PRC	The Company	2025SR2070251	October 24, 2025	Not published	–
11	TCM Production Quality Intelligent Supervision System.	PRC	The Company	2025SR2069544	October 24, 2025	Not published	–
12	Chronic Disease Treatment Plan Intelligent Management System.	PRC	The Company	2025SR1998334	October 16, 2025	Not published	–
13	AI-Driven Chronic Disease Management System.	PRC	The Company	2025SR1998344	October 16, 2025	Not published	–
14	Intelligent TCM Auxiliary Diagnosis System	PRC	The Company	2025SR1997875	October 16, 2025	Not published	–
15	Intelligent TCM Efficacy Evaluation System	PRC	The Company	2025SR1997892	October 16, 2025	Not published	–
16	Intelligent Prescription Management System	PRC	The Company	2024SR0967022	July 9, 2024	October 10, 2023	December 31, 2073
17	Online Triage System	PRC	The Company	2024SR0966020	July 9, 2024	November 1, 2023	December 31, 2073
18	Smart Scheduling System	PRC	The Company	2024SR0966023	July 9, 2024	March 19, 2024	December 31, 2074
19	TCM Evaluation System	PRC	The Company	2024SR0968333	July 9, 2024	May 10, 2024	December 31, 2074
20	Intelligent Prescription Review System	PRC	The Company	2024SR0968336	July 9, 2024	April 15, 2024	December 31, 2074
21	Gaozhentang Cloud HIS System.	PRC	The Company	2024SR0967020	July 9, 2024	October 30, 2023	December 31, 2073
22	Doctor Consultation System	PRC	The Company	2024SR0966525	July 9, 2024	November 1, 2023	December 31, 2073
23	Payment Settlement Management System	PRC	The Company	2024SR0966018	July 9, 2024	October 19, 2023	December 31, 2073
24	Intelligent Prescription Management System (2)	PRC	The Company	2024SR0966526	July 9, 2024	March 28, 2024	December 31, 2074
25	Cloud Computing Analysis System	PRC	The Company	2024SR0956201	July 8, 2024	May 11, 2024	December 31, 2074
26	Gaozhentang Video Management System	PRC	The Company	2024SR0517221	April 17, 2024	Not published	–
27	Gaozhentang Interactive Live Mini Program	PRC	The Company	2023SR0760198	June 29, 2023	Not published	–

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

(ii) Work Copyright

No.	Copyright	Place of Registration	Copyright owner	Registration No.	Date of Registration	Expiration date
1	Yuyantang	PRC	The Company	國作登字-2025-F-00315815	October 29, 2025	December 31, 2075
2	Yuyantang	PRC	The Company	國作登字-2025-F-00314600	October 28, 2025	December 31, 2075
3	Yuyantang	PRC	The Company	國作登字-2025-F-00314601	October 28, 2025	December 31, 2075
4	Gaozhentang Full Lifecycle Diagnosis and Treatment Model	PRC	The Company	國作登字-2025-K-00051713	February 20, 2025	December 31, 2075
5	Gaozhentang Diagnosis and Treatment Process	PRC	The Company	國作登字-2025-K-00051714	February 20, 2025	December 31, 2075
6	Gaozhentang Logo	PRC	The Company	國作登字-2025-F-00017549	January 15, 2025	December 31, 2075
7	Gaozhentang TCM Clinic	PRC	The Company	國作登字-2023-F-00142390	July 13, 2023	December 31, 2073
8	Compilation of 50 Diseases – TCM vs Western Medicine Comparison	PRC	The Company	國作登字-2022-A-10256889	December 9, 2022	December 31, 2072

(c) Patent

No.	Patent	Patent owner	Patent Type	Patent number	Application date	Expiration date
1	High-temperature transfer tank for Chinese herbal medicine slices and extracts.	The Company; Harbin Yuyantang	Invention	202210097529.4	January 27, 2022	January 26, 2037
2	Packaging Box for Canhurenfei Lung-Moistening Granules.	The Company; Harbin Yuyantang	Appearance design	202330737215.1	November 10, 2023	November 9, 2038
3	Packaging Box for Yiju Liver-Regulating Granules	The Company; Harbin Yuyantang	Appearance design	202330737929.2	November 12, 2023	November 11, 2038
4	Packaging Box for Zhijiang Tongluo Powder	The Company; Harbin Yuyantang	Appearance design	202330731774.1	November 9, 2023	November 8, 2038
5	Packaging Box for Wucan Qingxin Granules	The Company; Harbin Yuyantang	Appearance design	202330737200.5	November 10, 2023	November 9, 2038
6	Packaging Box for Guirong Kidney-Tonifying Granules	The Company; Harbin Yuyantang	Appearance design	202330737921.6	November 12, 2023	November 11, 2038
7	Multifunctional Foot Acupoint Massage Device for Traditional Chinese Medicine (TCM)	The Company; Harbin Yuyantang	Utility Mode	202221135554.9	May 12, 2022	May 11, 2032
8	Simple Lumbar Traction Device.	The Company; Harbin Yuyantang	Utility Mode	202221135071.9	May 12, 2022	May 11, 2032
9	High-Temperature Transfer Tank for Decoction Liquids and Herbal Extracts	The Company; Harbin Yuyantang	Utility Mode	202220222690.5	January 27, 2022	January 26, 2032
10	Handbag for Gaozhentang TCM Clinic	The Company; Harbin Yuyantang	Appearance design	202230199444.8	April 11, 2022	April 10, 2037
11	Multistage Ultrafine Pulverization Device	The Company; Harbin Yuyantang	Utility Mode	202122635406.5	November 1, 2021	October 31, 2031
12	Continuous Dynamic Extraction and Separation Process for Traditional Chinese Medicine (TCM)	The Company; Harbin Yuyantang	Invention	202011450636.8	December 9, 2020	December 8, 2040
13	Ultrafine Powder Filling Device.	The Company; Harbin Yuyantang	Utility Mode	202122635492.X	November 1, 2021	October 31, 2031
14	Automatic Grinding Device for Medicinal Herbs.	The Company; Harbin Yuyantang	Utility Mode	202021057381.4	June 10, 2020	June 9, 2030
15	Peeling and Slicing Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054538.7	December 8, 2018	December 7, 2028
16	Cleaning–Peeling–Slicing Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054543.8	December 8, 2018	December 7, 2028
17	Cleaning–Peeling Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054541.9	December 8, 2018	December 7, 2028
18	Integrated Cutting–Cleaning–Clamping Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054544.2	December 8, 2018	December 7, 2028
19	Cutting Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054546.1	December 8, 2018	December 7, 2028
20	Peeling–Slicing–Drying Device for Herbal Processing	The Company; Harbin Yuyantang	Utility Mode	201822054551.2	December 8, 2018	December 7, 2028

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

3. Domain names

As of May 31, 2026, we owned the following domain names which we consider to be or may be material to our business:

No.	Domain name	Domain owner	Registration date	Expiration date
1	yytzy.cn	Heilongjiang Gaozhentang Medical Management	July 16, 2025	July 16, 2035
2	yuyantangzhongyi.cn	Heilongjiang Gaozhentang Medical Management	July 16, 2025	July 16, 2035
3	yuyantangzhongyi.com	Harbin Yuyantang	November 7, 2025	November 7, 2035
4	膏珍雲醫.com	Harbin Yuyantang	October 28, 2020	October 28, 2028
5	膏珍雲醫.cn	Harbin Yuyantang	October 28, 2020	October 28, 2028
6	膏珍堂中醫.com	Harbin Yuyantang	October 28, 2020	October 28, 2028
7	膏珍堂中醫.cn	Harbin Yuyantang	October 28, 2020	October 28, 2028
8	gaozhentang.cn	Harbin Yuyantang	November 25, 2019	November 25, 2034
9	譽研堂.cn	Harbin Yuyantang	November 27, 2019	November 27, 2034
10	膏珍堂.com	Harbin Yuyantang	June 27, 2019	June 27, 2035
11	膏珍堂.cn	Harbin Yuyantang	June 27, 2019	June 27, 2035
12	譽研堂.com	Heilongjiang Yuyantang Pharmaceutical	November 27, 2019	November 27, 2034
13	gaozhentang.com	Heilongjiang Gaozhentang Medical Management	October 24, 2025	October 24, 2035
14	gaozhentangjituan.icu	Heilongjiang Gaozhentang Medical Management	April 24, 2024	April 24, 2029

Save as aforesaid, as of 31 May, 2026, there were no other trade or service marks, patents, intellectual or industrial property rights which were material in relation to our business.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

C. FURTHER INFORMATION ABOUT OUR DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of interests of Directors and Chief Executive of the Company

Save as disclosed below, immediately following the completion of the [REDACTED] (assuming that the [REDACTED] is not exercised), so far as our Directors are aware, none of our Directors or chief executive has any interests or short positions in our Shares, underlying Shares and debentures of our Company or its associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to our Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he or she is taken or deemed to have under such provisions of the SFO) or which will be required, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or which will be required to be notified to our Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Companies contained in the Listing Rules.

(a) Interest in our Company

<u>Name of Director, and chief executive</u>	<u>Nature of Interest</u>	<u>Number and class of Shares⁽¹⁾</u>	<u>Approximate percentage of shareholding in the total issued share capital of our Company immediately upon completion of the [REDACTED]⁽²⁾</u>
Mr. Guo Yang	Interest in controlled corporations/ deemed interest	123,163,656	[REDACTED]%
Mr. Gao Lifu	Interest in controlled corporations/ deemed interest	116,400,840	[REDACTED]%

Note:

(1) All interests stated are long positions.

(2) The calculation is based on the total number of [REDACTED] Domestic Shares in issue and [REDACTED] H Shares in issue immediately after the completion of the [REDACTED] (without taking into account the H Shares may be issued upon the exercise of the [REDACTED]).

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

2. Disclosure of Interests of Substantial Shareholders

(a) Interests in our Company

For information on the persons who will, immediately following the completion of the [REDACTED] having or be deemed or taken to have interests or short positions in our Shares or underlying Shares which would be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or directly or indirectly be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company, see the section headed “Substantial Shareholders” in this document and “C. Further Information about our Directors and Senior Management — 1. Disclosure of Interests of Directors and Chief Executive of the Company” in this section.

(b) Interests of the Substantial Shareholders of Other Members of Our Group

As of the Latest Practicable Date, so far as our Directors are not aware of any persons (other than our Directors or chief executive of our Company) who will, immediately following the completion of the [REDACTED], directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of our Group.

3. Service Contracts

We have entered into a contract with each of our Directors in respect of, among other things, compliance with the relevant laws and regulations, the Articles of Association and applicable provisions on arbitration.

Save as disclosed above, we have not entered, and do not propose to enter, into any service contracts with any of our Directors in their respective capacities as Directors (other than contracts expiring or determinable by the employer within one year without any payment of compensation (other than statutory compensation)).

4. Director’s Remuneration

Save as disclosed in the section headed “Directors and Senior Management” and Note 8 to “Appendix I — Accountants’ Report” for the years ended December 31, 2023, 2024, 2025 and five months ended May 31, 2026, none of our Directors received other remunerations of benefits in kind from us.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

5. Disclaimers

Saved as disclosed in this document:

- (a) none of our Directors or any of the parties listed in “— E. Other Information — 4. Qualification of Experts” below is:
 - (i) interested in our promotion, or in any assets which, within the two years immediately preceding the date of this document, have been acquired or disposed of by or leased to us, or are proposed to be acquired or disposed of by or leased to our Company;
 - (ii) materially interested in any contract or arrangement subsisting at the date of this document which is significant in relation to our business;
- (b) save in connection with the [REDACTED], none of the parties listed in “— E. Other Information — 4. Qualification of Experts” below:
 - (i) is interested legally or beneficially in any shares in any member of our Group; or
 - (ii) has any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for any securities in any member of our Group;
- (c) none of our Directors or their close associates or any shareholders of our Company who to the knowledge of our Directors owns more than 5% of our issued share capital has any interest in our top five customers or suppliers; and
- (d) none of our Directors is a director or employee of a company that has an interest in the share capital of our Company which, once the H Shares are [REDACTED] on the Stock Exchange, would have to be disclosed pursuant to Divisions 2 and 3 of Part XV of the SFO.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

D. OUR INCENTIVE SCHEMES

1. Background

The Company has adopted an Employee Incentive Scheme. As of the Latest Practicable Date, 845,352 Shares were held by the Employee Incentive Platform, representing approximately 5.34% of the aggregate amount of the Shares in issue immediately before the completion of the [REDACTED]. The voting rights in our Company of the Employee Incentive Platform shall be exercised by its general partner, being Mr. Guo Yang, our executive Director, pursuant to the partnership agreement. As the Employee Incentive Scheme does not involve the grant of options by our Company to subscribe for new Shares, the terms of the Employee Incentive Scheme are not subject to the provisions of Chapter 17 of the Listing Rules, except for the disclosure requirement under Rule 17.12 of the Listing Rules.

2. Purposes of the Employee Incentive Scheme

The purpose of the Employee Incentive Scheme is to incentivize the management team, retain talent and promote its long-term sustainable development.

3. Awards

An award under the Employee Incentive Scheme (the “**Award(s)**”) gives a participant in the Employee Incentive Scheme a conditional right when granted the Award to obtain interests in the Employee Incentive Platform.

4. Maximum number of Shares

The number of Shares held by the Employee Incentive Platform under the Employee Incentive Scheme is 845,352 Shares, representing approximately 5.34% of the aggregate amount of the Shares in issue immediately before the completion of the [REDACTED] and [REDACTED]% of our total issued share capital immediately upon completion of the [REDACTED] assuming the [REDACTED] is not exercised.

5. Participants

Participants of the Employee Incentive Scheme (the “**Participants**”) include management, officers and existing employees of the Company or any other member of the Group.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

6. Term of the Scheme

The provisions of the Employee Incentive Scheme shall in all aspects remain in full force and effect and all the Awards granted to the Participants under the Employee Incentive Scheme shall continue to be held by the Employee Incentive Platform and become vested in the Participants according to the conditions of the Award, subject to the receipt by the Employee Incentive Platform of the transfer documents prescribed by the Employee Incentive Platform and duly executed by the Participants.

7. Grant and Acceptance of Award

On and subject to the limitations and conditions of the Employee Incentive scheme, the Company shall be entitled at any time during the term of the Employee Incentive Scheme to make a grant to any Participant at discretion. Each of the grantees has entered into an acceptance agreement with the Company on acknowledgment of the grant.

8. Rights Attached to the Awards

A Participant shall not have any interest or rights (including the right to receive dividends) in the Awards prior to the date on which an Award is vested on the Participant (the “**Vesting Date**”). No instructions shall be given by a Participant (including, without limitation, voting rights) in respect of the Awards that have not been vested.

9. Awards to be personal to the Grantee

Prior to the Vesting Date, any Award made under the Employee Incentive Scheme shall be personal to the Participant to whom it is made and shall not be assignable and no Participant shall in any way sell, transfer, charge, mortgage, encumber or create any interest in favor of any other person over or in relation to the Awards referable to him pursuant to such Award.

10. Repurchase of Award

Any unvested Awards shall be unconditionally repurchased by the general partner of the Employee Incentive Platform, or a person or an entity the Company designated (the “**Designated Person**”) where such Participant’s employment or service with the Group is terminated for any reason; or such Participant involved in any misconduct that invokes detrimental impacts on the Company.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

11. Takeovers and Mergers, Compromise or Arrangement and Voluntary Winding-up

If there occurs an event of change in control of the Company, whether by way of offer, merger, scheme of arrangement or otherwise prior to the vesting date, the adjustments, modifications or termination of outstanding Awards shall be determined by the Company.

12. Administration of the Employee Incentive Scheme

The Employee Incentive Scheme shall be subject to the administration of the Administrator, being the chief executive officer of the Company, in accordance with the rules of the Employee Incentive Scheme, including the power to construe and interpret these Scheme Rules and the terms of the Awards granted under it.

13. Details of the Awards granted

As of the Latest Practicable Date, an aggregate number of Shares underlying the Awards held by the Employee Incentive Platform amounted to 845,351 Shares, representing approximately 5.34% of our Company’s total issued share capital immediately prior to the [REDACTED], had been granted to 52 Participants.

Other material information of the Awards granted pursuant to the Employee Incentive Scheme as of the Latest Practicable Date are set out as below:

- (a) Details of the Awards granted to Directors, supervisors, senior management, and connected persons of our Company:

<u>Grantee</u>	<u>Relationship with the Company</u>	<u>Number of Shares underlying the Awards held by the Employee Incentive Platform (as of the Latest Practicable Date)</u>	<u>Approximately shareholding percentage in the total issued Shares immediately prior to the [REDACTED]</u>
Director			
Mr. Guo Yang (郭陽)	Chairman of the Board, executive Director and general manager	235,351	[REDACTED]
Mr. Gao Lifu (高立福)	Executive Director and vice general manager	118,500	[REDACTED]
Ms. Jiang Yujuan (姜玉娟)	Executive Director	3,000	[REDACTED]
Supervisors			
Ms. Guo Yi (郭一)	Chairwoman of the Supervisory Committee	20,500	[REDACTED]
Mr. Chen Gang (陳剛)	Supervisor	10,000	[REDACTED]
Ms. Liu Yanxue (劉艷雪)	Supervisor	10,500	[REDACTED]
Senior Management			
Mr. Yan Haitao (閔海濤)	Chief financial officer	20,300	[REDACTED]

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Grantee	Relationship with the Company	Number of Shares underlying the Awards held by the Employee Incentive Platform (as of the Latest Practicable Date)	Approximately shareholding percentage in the total issued Shares immediately prior to the [REDACTED]
Connected Persons			
Mr. Chen Lin (陳林)	Director and Manager of Changchun Yuyuan Gaozhen Tang Medical Service Co., Ltd.* (長春譽遠膏珍堂醫療服務有限公司)	35,300	[REDACTED]
Mr. Ning Fulin (寧福林)	Supervisor of Changchun Yuyuan Gaozhen Tang Medical Service Co., Ltd.* (長春譽遠膏珍堂醫療服務有限公司)	60,500	[REDACTED]

- (b) Our Company also granted 331,400 Awards to the other 43 grantees, representing approximately 2.09% of our Company’s total issued share capital immediately prior to the [REDACTED].

E. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Group.

2. Litigation

So far as our Directors are aware, no litigation or claim of material importance is pending or threatened against any member of our Group.

3. Joint Sponsors

The Joint Sponsors have made an [REDACTED] on behalf of our Company to the Hong Kong Stock Exchange for the [REDACTED] of, and [REDACTED] to deal in, the H Shares of our Company. All necessary arrangements have been made enabling the H Shares to be [REDACTED] into [REDACTED].

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

Each of the Joint Sponsors satisfies the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules.

Pursuant to the engagement letters entered into between our Company and each of the Joint Sponsors, the Joint Sponsors’ fees payable by us to the Joint Sponsors in respect of their services as sponsors in connection with the [REDACTED] on the Stock Exchange is approximately HK\$[REDACTED].

4. Compliance Adviser

Our Company has appointed Guoyuan Capital (Hong Kong) Limited as our compliance adviser in compliance with Rule 3A.19 of the Listing Rules.

5. Qualifications and Consents of Experts

The following experts have each given and have not withdrawn their respective written consents to the issue of this document with copies of their reports, letters, opinions or summaries of opinions (as the case may be) and the references to their names included herein in the form and context in which they are respectively included.

<u>Name</u>	<u>Qualification</u>
CMB International Capital Limited	Licensed corporation under the SFO to conduct Type 1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities under the SFO.
Guoyuan Capital (Hong Kong) Limited	Licensed corporation under the SFO to conduct Type 6 (advising on corporate finance) regulated activity under the SFO.
Tian Yuan Law Firm	Legal adviser as to the laws of the PRC to our Company (including as to PRC data compliance)
Ernst & Young	Certified Public Accountants. Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance.
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Independent industry consultant
Henan Chongmiao Fire Safety Technology Co., Ltd.* (河南崇淼消防科技有限公司)	Fire Safety Consultant

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

As of the Latest Practicable Date, none of the experts named above has any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

6. Binding Effect

This document shall have the effect, if an application is made in pursuance hereof, of rendering all persons concerned bound by all the provisions (other than the penal provisions) of sections 44A and 44B of the Companies Ordinance so far as applicable.

7. No Material Adverse Change

The Directors confirm that there has been no material change in our financial or trading position since May 31, 2026.

8. Taxation of Holders of H Shares

The sale, purchase and transfer of H Shares are subject to Hong Kong stamp duty if such sale, purchase and transfer are effected on the H Share register of members of our Company, including in circumstances where such transactions are effected on the Stock Exchange. The current rate of Hong Kong stamp duty for such sale, purchase and transfer on each of the purchaser and the seller is 0.10% of the consideration or, if higher, the fair value of the H Shares being sold or transferred.

9. Restriction on Share Repurchases

For details of the restrictions on share repurchases by our Company, please refer to “Summary of the Articles of Association — Increase, Reduction and Repurchase of Shares — Repurchase of Shares” in Appendix III to this document.

10. Promoters

The promoters of the Company are:

No.	Name
1	Yuyantang Investment
2	Zhitongdaohe Investment
3	Zhitongdaohe Yidai
4	Hainan Youzhuo

Within the two years immediately preceding the date of this document, no cash, securities or benefit has been paid, allotted or given, or is proposed to be paid, allotted or given to the promoters named above in connection with the [REDACTED] or the related transactions described in this document.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

11. Preliminary Expenses

The Company did not incur material preliminary expenses for the purpose of the Listing Rules.

12. Miscellaneous

- (a) Save as disclosed in “Changes in Share Capital” above, within the two years immediately preceding the date of this document:
 - (i) no share or loan capital or debenture of our Company or any of our subsidiaries has been issued or agreed to be issued or is proposed to be issued for cash or as fully or partly paid other than in cash or otherwise;
 - (ii) no share or loan capital of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option; and
 - (iii) no commissions, discounts, brokerages or other special terms have been granted or agreed to be granted in connection with the issue or sale of any share or loan capital of our Company or any of our subsidiaries.
- (b) There are no founder, management or deferred shares nor any debentures in our Company or any of our subsidiaries.
- (c) There are no share or loan capital or debenture of our Company or any of our subsidiaries is under option or is agreed conditionally or unconditionally to be put under option.
- (d) Save as disclosed in this document, no commissions, discounts, brokerages or other special terms have been granted in connection with the issue or sale of any share or loan capital of our Company or any of its subsidiaries by our Company for subscribing or agreeing to subscribe, or procuring or agreeing to procure subscriptions, for any shares in or debentures of our Company or any of our subsidiaries.

APPENDIX IV

STATUTORY AND GENERAL INFORMATION

- (e) Save as disclosed in the paragraph headed “B. Further Information about our Business — 1. Summary of Material Contracts” in this section, none of our Directors or proposed Directors or experts (as named in this document), have any interest, direct or indirect, in any assets which have been, within the two years immediately preceding the date of this document, acquired or disposed of by or leased to, any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group. Save as disclosed in this document, no equity or debt securities of any company within our Group is presently [REDACTED] on any stock exchange or traded on any trading system nor is any [REDACTED] or [REDACTED] or proposed to be sought.
- (f) Our Company has no outstanding convertible debt securities or debentures.
- (g) There is no arrangement under which future dividends are waived or agreed to be waived.
- (h) There has not been any interruption in the business of our Group which may have or has had a significant effect on the financial position of our Group in the 12 months preceding the date of this document.
- (i) We currently do not intend to apply for the status of a Sino-foreign investment joint stock limited company and do not expect to be subject to the PRC Sino-Foreign Joint Venture Law.

13. Bilingual Document

The English language and Chinese language versions of this document are being published separately in reliance upon the exemption provided by section 4 of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong).